ARK Genomic Revolution ETF
ARKG
271 hedge funds and large institutions have $1.48B invested in ARK Genomic Revolution ETF in 2026 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 61 increasing their positions, 49 reducing their positions, and 21 closing their positions.
276% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 21
99% more capital invested
Capital invested by funds: $743M → $1.48B (+$735M)
24% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 49
24% more funds holding
Funds holding: 219 → 271 (+52)
19.28% more ownership
Funds ownership: 72.06% → 91.35% (+19%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
40% less call options, than puts
Call options by funds: $189M | Put options by funds: $317M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$59.5M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$33.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$21.6M |
| 4 |
D.E. Shaw & Co
New York
|
+$10.1M |
| 5 |
Citigroup
New York
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.37M |
| 2 |
Walleye Trading
New York
|
-$2.26M |
| 3 |
Jane Street
New York
|
-$1.64M |
| 4 |
Mariner
Overland Park,
Kansas
|
-$1.42M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.32M |
ARKG Hedge Fund Activity: Q2 2026 in Review
271 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2026, worth a combined $1.48B — up 99% from $743M a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new ARKG positions and 21 closed out — a net gain of 58 holders — while 61 added to existing stakes and 49 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $59.5M. The largest seller was Citadel Advisors, exiting entirely with an estimated $9.37M sold.
- 271 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2026, up from 219 in Q1 2026.
- Funds reported $1.48B of ARK Genomic Revolution ETF stock for Q2 2026, up 99% quarter-over-quarter.
- 79 funds opened new ARK Genomic Revolution ETF positions in Q2 2026 and 21 closed out, a net change of +58 holders.
- The largest ARK Genomic Revolution ETF buyer in Q2 2026 was Morgan Stanley, an estimated $59.5M added.
- The largest ARK Genomic Revolution ETF seller in Q2 2026 was Citadel Advisors, an estimated $9.37M sold.
Based on aggregated 13F filings for Q2 2026.